Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.38 |
| ▸ | USP5 | P45974 | 1/20 | 0.38 |
| ▸ | USP9X | Q93008 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1315048 | 1.00 | STAT3 (0.48) | STAT3HTTUCHL1USP5USP9X | |
| SCHEMBL13474828 | 1.00 | STAT3 (0.48) | STAT3HTTUCHL1USP5USP9X | |
| SCHEMBL1315051 | 1.00 | STAT3 (0.48) | STAT3HTTUCHL1USP5USP9X | |
| SCHEMBL1315044 | 1.00 | STAT3 (0.48) | STAT3HTTUCHL1USP5USP9X | |
| SCHEMBL13474843 | 0.85 | HTT (0.40) | STAT3HTTCNR2ALDH1A1POLB | |
| SCHEMBL14403128 | 0.85 | HTT (0.40) | STAT3HTTCNR2ALDH1A1POLB | |
| SCHEMBL1316380 | 0.74 | LMNA (0.61) | STAT3HTTUCHL1USP5USP9X | |
| SCHEMBL1316383 | 0.74 | LMNA (0.61) | STAT3HTTUCHL1USP5USP9X | |
| SCHEMBL1316385 | 0.74 | LMNA (0.61) | STAT3HTTUCHL1USP5USP9X | |
| SCHEMBL1316382 | 0.74 | LMNA (0.61) | STAT3HTTUCHL1USP5USP9X |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101454275-B | Orally bioavailable caffeic acid related anticancer drugs | UNIV TEXAS | 2014-07-23 | — | — | CN | disclosed |
| US-20130129675-A1 | INTERFERON THERAPIES IN COMBINATION WITH BLOCKADE OF STAT3 ACTIVATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-23 | — | — | US | disclosed |
| US-20110275577-A1 | METHODS OF TREATING DERMATOLOGIC, GYNECOLOGIC, AND GENITAL DISORDERS WITH CAFFEIC ACID ANALOGS | MOLECULIN, LLC (US) | 2011-11-10 | — | — | US | disclosed |
| CN-101454275-A | Orally bioavailable caffeic acid related anticancer drugs | UNIV TEXAS (US) | 2009-06-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275577-A1 | METHODS OF TREATING DERMATOLOGIC, GYNECOLOGIC, AND GENITAL DISORDERS WITH CAFFEIC ACID ANALOGS | VHL, PRKDC, POLR1C | STAT3 902/4885HTT 4002/4885UCHL1 3312/4885 |
| US-20130129675-A1 | INTERFERON THERAPIES IN COMBINATION WITH BLOCKADE OF STAT3 ACTIVATION | STAT3, STAT1, STAT5B | STAT3 1/4885HTT 3190/4885UCHL1 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.